Vor Biopharma Inc. (NYSE:VOR) Receives Average Recommendation of “Buy” from Brokerages

Shares of Vor Biopharma Inc. (NYSE:VOR) have earned an average rating of “Buy” from the seven brokerages that are covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a buy rating. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $11.36.

Several equities research analysts have recently issued reports on the stock. JMP Securities restated a “market outperform” rating and issued a $12.00 target price on shares of Vor Biopharma in a report on Friday, September 6th. HC Wainwright restated a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a report on Friday, November 8th. Robert W. Baird dropped their price target on Vor Biopharma from $22.00 to $14.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Wedbush reaffirmed an “outperform” rating and issued a $11.00 price target on shares of Vor Biopharma in a research report on Friday, November 8th. Finally, Barclays dropped their price objective on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research note on Wednesday, August 14th.

Institutional Trading of Vor Biopharma

A number of institutional investors have recently modified their holdings of VOR. Renaissance Technologies LLC lifted its position in Vor Biopharma by 48.0% during the second quarter. Renaissance Technologies LLC now owns 495,300 shares of the company’s stock valued at $495,000 after acquiring an additional 160,642 shares during the last quarter. Rosalind Advisors Inc. purchased a new stake in shares of Vor Biopharma during the 3rd quarter valued at $54,000. Vanguard Group Inc. boosted its position in shares of Vor Biopharma by 4.0% in the 1st quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after purchasing an additional 69,436 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. acquired a new stake in shares of Vor Biopharma in the 2nd quarter worth $63,000. Finally, Acadian Asset Management LLC purchased a new position in Vor Biopharma during the 1st quarter worth $126,000. 97.29% of the stock is currently owned by institutional investors.

Vor Biopharma Stock Performance

VOR stock opened at $0.79 on Friday. The firm has a market cap of $54.35 million, a PE ratio of -0.48 and a beta of -0.40. The firm has a fifty day moving average price of $0.77 and a 200 day moving average price of $0.99. Vor Biopharma has a fifty-two week low of $0.63 and a fifty-two week high of $3.14.

Vor Biopharma (NYSE:VOR) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.40) EPS for the quarter, meeting analysts’ consensus estimates of ($0.40). On average, equities analysts predict that Vor Biopharma will post -1.55 EPS for the current year.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.